63792-75-6

Upstream product

• 16937-99-8 N-Boc-D-Leu 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 87976-66-7 Boc-D-Leu-Phe-OMe 

Downstream Products

• 1006104-48-8 C₂₆H₄₁N₃O₆ 
• 242148-28-3 3',5'-dimethylphenyl-ureido-(Phe-D-Leu)₂-Phe-OMe 
• 242148-24-9 m-tolylureido-Phe-D-Leu-Phe-D-Leu-Phe-OMe 
• 242148-26-1 p-tolylureido-Phe-D-Leu-Phe-D-Leu-Phe-OMe 
• 66556-73-8 Boc-FL(D)FL(D)F 
• 128175-89-3 Boc-Phe-D-Leu-Phe-D-Leu-Phe-OMe 
• 242148-29-4 isopropylureido-Phe-D-Leu-Phe-D-Leu-Phe-OMe 
• 63792-78-9 D-Leu-Phe-D-Leu-Phe-OMe 
• 909108-60-7 (S)-2-((R)-2-{(S)-2-[(S)-2-((S)-2-Amino-4-methyl-pentanoylamino)-4-methyl-pentanoylamino]-3-methyl-butyrylamino}-4-methyl-pentanoylamino)-3-phenyl-propionic acid 
• 909108-59-4 (S)-2-((R)-2-{(S)-2-[(S)-2-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-4-methyl-pentanoylamino]-3-methyl-butyrylamino}-4-methyl-pentanoylamino)-3-phenyl-propionic acid methyl ester 
• 951005-64-4 (S)-2-[(R)-2-((S)-2-Amino-3-methyl-butyrylamino)-4-methyl-pentanoylamino]-3-phenyl-propionic acid methyl ester 
• 934715-41-0 2-(2-{2-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-4-methyl-pentanoylamino]-butyrylamino}-4-methyl-pentanoylamino)-3-phenyl-propionic acid methyl ester 
• 934715-78-3 2-(2-{2-[2-(2-amino-4-methyl-pentanoylamino)-4-methyl-pentanoylamino]-butyrylamino}-4-methyl-pentanoylamino)-3-phenyl-propionic acid 
• 934715-40-9 2-[2-(2-amino-butyrylamino)-4-methyl-pentanoylamino]-3-phenyl-propionic acid methyl ester 

Relevant academic research and scientific papers

Comprehensive study of sansalvamide A derivatives and their structure-activity relationships against drug-resistant colon cancer cell lines

We report an extensive structure-activity relationship (SAR) of 62 compounds active against two drug-resistant colon cancer cell lines. Our comprehensive evaluation of two generations of compounds utilizes SAR, NMR, and molecular modeling to evaluate the

Synthesis and cytotoxicity of a new class of potent decapeptide macrocycles

(Chemical Equation Presented) Described are the syntheses of five decapeptides that are C-2-symmetrical derivatives of the natural product pentapeptide sansalvamide A. Derivatives were made using a succinct convergent synthesis. These analogues share no s

Synthesis of second-generation Sansalvamide A derivatives: Novel templates as potential antitumor agents

We report the synthesis of 34 second-generation Sansalvamide A derivatives. San A derivatives have unique anticancer properties and target multiple cancers, including colon, pancreatic, breast, prostate, and melanoma. As novel templates, the derivatives d

Synthesis of Sansalvamide A derivatives and their cytotoxicity in the MSS colon cancer cell line HT-29

We report the synthesis of thirty-six Sansalvamide A derivatives, and their biological activity against colon cancer HT-29 cell line, a microsatellite stable (MSS) colon cancer cell-line. The thirty-six compounds can be divided into three subsets, where t

High-yielding macrocyclization conditions used in the synthesis of novel Sansalvamide A derivatives

Described are the syntheses of nine Sansalvamide A derivatives using new, high-yielding, in situ deprotection-cyclization conditions that are general for this series of macrocycles, 55% average for both steps. This is 10-fold greater than previously repor

Conformational aspects of human formylpeptide receptor antagonists

The conformation of several Phe-D-Leu-Phe-D-Leu-Phe analogues was analyzed using infrared absorption and circular dichroism. Their effect on human neutrophils was verified by receptor binding and chemotaxis assays. The results demonstrate that the compounds examined prefer an ordered conformation (β-turn) in amphipatic environment, and that they are able to antagonize the neutrophil functions evoked by CHO-Met-Leu-Phe.